[
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The conceptual framework for this assessment is outlined in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Considerations on the included data\nThe Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCharacteristics of the included human studies (body of evidence) from the systematic literature search\n\nCD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The Panel notes that the studies selected were heterogeneous with respect to the length of follow‐up, the methods and criteria used for the assessment of (health) outcomes, the study design, the way in which the exposure was assessed (i.e. the timing of introduction of CFs), the classification into exposure groups, the study settings and the populations investigated (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CD: coeliac disease; CF: complementary food; m: months; RoB: risk of bias; T1DM: type 1 diabetes mellitus. * EFSA (2017b); **For the complete list of outcomes, please see Figure 1 (Section 1.6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The practical steps are described in the following sections and summarised in Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This hierarchy of the available evidence is described in Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The approach for integrating the evidence and grading the confidence in the evidence is described in Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "An overview is presented in Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  }
]